Nanuka Tsibadze and colleagues at Jefferson Einstein Philadelphia conducted a nationwide retrospective analysis of 4,104 PsA patients on GLP-1s versus 86,432 PsA patients not on GLP-1s. The results: Mortality: 1.4% in the GLP-1 group vs
doi: 10.1210/er.2008-0027 33 LugerAPragerRGaubeSGrafHKlauserRSchernthanerG
The supplier does not provide quotations for this product through SelectScience
In contrast, Bydureon is a long-acting, once-weekly formulation, developed using a microsphere-based delivery system
Slow Titration for Sensitive Patients Some women experience significant gastrointestinal side effects when starting GLP-1 therapy
We offer transparent, all inclusive pricing for your care, which covers your online visits with your provider, your medication, direct access to your provider through secure messaging, and over $3,700 in partnership perks and expert-led resources to support a healthy lifestyle change all for one low price